Tilray Brands, Inc.
TLRY- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001731348
In the last 90 days, Tilray Brands, Inc. insiders filed 3 open-market purchases and 0 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $125.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Tilray Brands, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 3 filings
- 3 insiders, $69.2K in total
- Open-market sells
- 0 filings
- Insiders trading
- 3
- Net value
- +$69.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Tilray Brands, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Simon Irwin D | President and CEO | 1,309,031 | Aug 27, 2026 | 2 |
| Merton Carl A | Chief Financial Officer | 215,556 | Aug 27, 2026 | 3 |
| Gendel Mitchell | Global General Counsel | 200,225 | Aug 27, 2026 | 3 |
| Faltischek Denise M | Chief Strategy Officer | 225,047 | Aug 27, 2026 | 3 |
| Persofsky Renah | Director | 155,357 | Jul 30, 2026 | 1 |
| Looney Thomas P. | Director | 397,520 | Jul 30, 2026 | 1 |
| Herhalt Johann Michael | Director | 195,561 | Jul 30, 2026 | 1 |
| Cohen Steven Michael | Director | 55,542 | Jul 30, 2026 | 2 |
| Clanachan David F | Director | 192,511 | Jul 30, 2026 | 1 |
| Hopkinson David G. | Director | 43,104 | Jul 30, 2026 | 2 |
| Butts Jodi L. | Director | 112,502 | Jul 30, 2024 | 0 |
| Kennedy Brendan | Director | 6,224,196 | Nov 9, 2022 | 0 |
| Robb Walter E IV | Director | – | Jul 27, 2022 | 0 |
| Meiers James R. | Chief Operations Officer | 85,631 | Jun 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 (view filing)9:29 AM ET | Aug 6 | 1 day | Gendel MitchellGlobal General Counsel | PPurchase | +2.50K | $4.43 | +$11.1K | +2.0%124.9K after | |
| Aug 4, 2026 (view filing)1:36 PM ET | Aug 4 | Same day | Merton Carl AChief Financial Officer | PPurchase | +10.0K | $4.62 | +$46.2K | +7.7%139.8K after | |
| Aug 4, 2026 (view filing)10:58 AM ET | Aug 3 | 1 day | Faltischek Denise MChief Strategy Officer | PPurchase | +2.50K | $4.78 | +$11.9K | +1.8%141.3K after | |
| Apr 22, 2026 (view filing) | Apr 21 | 1 day | Hopkinson David G.Director | SSale | −33.6K | $6.94 | −$232.9K | −100.0%0 after | |
| Aug 4, 2025 (view filing) | Jul 31 | 4 days | Gendel MitchellGlobal General Counsel | PPurchase | +6.00K | $0.58 | +$3.48K | +0.9%698.3K after | |
| Jul 30, 2025 (view filing) | Jul 30 | Same day | Simon Irwin DPresident and CEO | PPurchase | +165.0K | $0.61 | +$100.7K | +4.4%3.94M after | |
| Jul 30, 2025 (view filing) | Jul 30 | Same day | Merton Carl AChief Financial Officer | PPurchase | +33.5K | $0.60 | +$20.1K | +4.4%798.1K after | |
| Nov 18, 2024 (view filing) | Nov 15 | 3 days | Merton Carl AChief Financial Officer | PPurchase | +26.0K | $1.36 | +$35.4K | New position26.0K after | |
| Jan 18, 2024 (view filing) | Jan 17 | 1 day | Faltischek Denise MChief Strategy Officer | PPurchase | +10.0K | $2.05 | +$20.5K | +3.5%293.3K after | |
| Jan 16, 2024 (view filing) | Jan 16 | Same day | Gendel MitchellGlobal General Counsel | PPurchase | +7.20K | $1.98 | +$14.3K | +3.8%195.8K after | |
| Jan 12, 2024 (view filing) | Jan 12 | Same day | Gendel MitchellGlobal General Counsel | PPurchase | +5.40K | $1.87 | +$10.1K | +2.9%188.6K after | |
| Jan 12, 2024 (view filing) | Jan 12 | Same day | Simon Irwin DPresident and CEO | PPurchase | +53.7K | $1.88 | +$101.0K | +2.7%2.03M after | |
| Jan 12, 2024 (view filing) | Jan 12 | Same day | Merton Carl AChief Financial Officer | PPurchase | +20.0K | $1.87 | +$37.4K | New position20.0K after | |
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −350.0K | $3.78 | −$1.32M | −5.3%6.22M after | |
| Oct 7, 2022 (view filing) | Oct 5 | 2 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −350.0K | $2.91 | −$1.02M | −5.1%6.57M after | |
| Sep 8, 2022 (view filing) | Sep 6 | 2 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −350.0K | $3.22 | −$1.13M | −4.8%6.92M after | |
| Aug 9, 2022 (view filing) | Aug 5 | 4 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −350.0K | $3.91 | −$1.37M | −4.6%7.27M after | |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −350.0K | $3.09 | −$1.08M | −4.4%7.62M after | |
| Aug 6, 2021 (view filing) | Aug 4-5 | 2 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −600.0K | $14.27 | −$8.56M | −7.0%7.97M after | 2 lots |
| Jul 19, 2021 (view filing) | Jul 15-16 | 4 days | Kennedy BrendanDirector | SSaleClass 2 Common Stock | −600.0K | $14.36 | −$8.61M | −6.5%8.57M after | 3 lots |